Last reviewed · How we verify
NCT04603872
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
EARLY_PHASE1 trial testing CD19/BCMA Targeted CAR T-cells and dasatinib in Multiple Myeloma in Relapse in 120 participants. Currently enrolling.
1 November 2023
Quick facts
| Lead sponsor | Zhejiang University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 November 2020 |
| Primary completion | 1 November 2023 |
| Estimated completion | 1 November 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD19/BCMA Targeted CAR T-cells and dasatinib — full drug profile →
- CD19/BCMA Targeted CAR T-cells — full drug profile →
Conditions studied
- Multiple Myeloma in Relapse — all drugs for Multiple Myeloma in Relapse →
- Multiple Myeloma, Refractory — all drugs for Multiple Myeloma, Refractory →
- Acute Lymphoblastic Leukemia, in Relapse — all drugs for Acute Lymphoblastic Leukemia, in Relapse →
- Acute Lymphocytic Leukaemia Refractory — all drugs for Acute Lymphocytic Leukaemia Refractory →
Sponsor
Zhejiang University
Who can join
Adults 18 to 70, any sex, with Multiple Myeloma in Relapse or Multiple Myeloma, Refractory. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.
Xiao X, Huang S, Chen S, Wang Y, et al · · 2021 · cited 187× · PMID 34794490 · DOI 10.1186/s13046-021-02148-6 -
How I treat refractory CRS and ICANS after CAR T-cell therapy.
Jain MD, Smith M, Shah NN. · · 2023 · cited 174× · PMID 36989488 · DOI 10.1182/blood.2022017414 -
Mechanisms of CAR T cell exhaustion and current counteraction strategies.
Zhu X, Li Q, Zhu X. · · 2022 · cited 58× · PMID 36568989 · DOI 10.3389/fcell.2022.1034257 -
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2 -
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.
Hughes AD, Teachey DT, Diorio C. · · 2024 · cited 37× · PMID 39012374 · DOI 10.1007/s00281-024-01013-w -
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Yin Z, Zhang Y, Wang X. · · 2021 · cited 30× · PMID 34256851 · DOI 10.1186/s40364-021-00309-5 -
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
Cho SF, Xing L, Anderson KC, Tai YT. · · 2021 · cited 28× · PMID 34885245 · DOI 10.3390/cancers13236136 -
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.
Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, et al · · 2022 · cited 23× · PMID 35655707 · DOI 10.1080/2162402x.2022.2077898
Verify or expand the search:
- PubMed search for NCT04603872
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Myeloma in Relapse
Currently open trials in the same condition.
- NCT07096778 — Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT06822972 — HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM · Phase 2 · recruiting
- NCT07032129 — Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
- NCT07248176 — Universal CAR-T Cell Therapy for MM · NA · recruiting
- NCT06846905 — Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma. · recruiting
Other Zhejiang University trials
Trials by the same sponsor.
- NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
- NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
- NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
- NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04603872 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
- Last refreshed: 28 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04603872.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing